The Technical Analyst
Select Language :
Processa Pharmaceuticals, [PCSA]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Processa Pharmaceuticals, Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

Processa Pharmaceuticals, is listed at the  Exchange

4.19% $2.37

America/New_York / 28 mar 2024 @ 16:00


Processa Pharmaceuticals,: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 4.04 mill
EPS: -22.80
P/E: -0.100
Earnings Date: Mar 28, 2024
SharesOutstanding: 1.708 mill
Avg Daily Volume: 1.583 mill
RATING 2024-03-28
B-
Neutral
RATINGS
Rating CashFlow: Neutral
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Neutral
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
2/223/224/221/232/233/23
Revenuen/an/an/an/an/an/a
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.100 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.02x
Company: PE -0.100 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$0.410
(-82.68%) $-1.955
Date: 2024-03-29
Expected Trading Range (DAY)

$ 2.00 - 2.73

( +/- 15.31%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-02-07 Young David Buy 21 000 Common Stock
2024-02-06 Young David Buy 20 000 Common Stock
2024-02-01 Lin Patrick Buy 1 500 Common Stock
2024-01-31 Lin Patrick Buy 2 500 Common Stock
2024-01-30 Ng George K Buy 10 000 Common Stock
INSIDER POWER
80.75
Last 96 transactions
Buy: 3 072 832 | Sell: 401 546

Forecast: 16:00 - $2.38

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $2.38
Forecast 2: 16:00 - $2.38
Forecast 3: 16:00 - $2.38
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $2.37 (4.19% )
Volume 0.166 mill
Avg. Vol. 1.583 mill
% of Avg. Vol 10.48 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Processa Pharmaceuticals, Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for Processa Pharmaceuticals, Inc.

RSI

Intraday RSI14 chart for Processa Pharmaceuticals, Inc.

Last 10 Buy & Sell Signals For PCSA

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35buy$2.36N/AActive
Profile picture for
            Processa Pharmaceuticals, Inc.

PCSA

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.

Last 10 Buy Signals

Date Signal @
OGUSDMar 29 - 08:105.93
CGOUSDMar 29 - 08:1171.85
XCADUSDMar 29 - 08:091.460
SFUNDUSDMar 29 - 08:09$4.55
STRKUSDMar 29 - 08:09$14.22
LPTUSDMar 29 - 08:10$18.98
PBTCUSDMar 29 - 08:085 553.51
FTMUSDMar 29 - 08:10$0.984
CBKUSDMar 29 - 08:091.088
APTUSDMar 29 - 08:0917.13

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.